Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults
To evaluate the effect of ribavirin on second phase plasma hepatitis C virus (HCV)
 ribonucleic acid (RNA) decline in participants who receive ombitasvir/ABT-450/ritonavir and
 dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in
 treatment-naive HCV genotype (GT) 1a-infected adults.
Inclusion Criteria:

 1. Screening laboratory result indicating HCV genotype 1 (GT1) a infection.

 2. Chronic HCV infection.

 3. Subjects must be non-cirrhotic.

 4. Subjects must be able to understand and adhere to the study visit schedule and all
 protocol requirements as well as voluntarily sign and date an institutional review
 board (IRB) approved informed consent.

 Exclusion Criteria:

 1. Women who are pregnant or breastfeeding.

 2. Positive test result for hepatitis B surface antigen (HBsAg) or anti-human
 immunodeficiency virus antibody (HIV Ab) positive immunoassay.

 3. Clinically significant abnormalities or co-morbidities, other than HCV infection, that
 make the subject unsuitable for this study or treatment.

 4. Current enrollment in another interventional clinical study. Previous use of any HCV
 treatments including pegylated interferon (pegIFN), ribavirin, or any direct acting
 antiviral agent, either investigational or approved, for HCV including protease
 inhibitors, nucleoside or non-nucleoside polymerase inhibitors, or nonstructural viral
 protein 5A (NS5A) inhibitors.

 5. History or solid organ transplant.

 6. Screening laboratory analysis that shows abnormal results.